Analyst Reco. Cytokinetics, Incorporated Deutsche Boerse AG

Equities

KK3A

US23282W6057

Real-time Estimate Tradegate Other stock markets 14:53:54 2024-06-17 EDT			5-day change	1st Jan Change
49.2 ^EUR	-1.60%		+2.89%	-32.70%

01:30pm	Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants	CI
06-11	Cytokinetics Insider Sold Shares Worth $413,106, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cytokinetics Insider Sold Shares Worth $413,106, According to a Recent SEC Filing	06-11	MT
Cytokinetics Insider Sold Shares Worth $1,099,125, According to a Recent SEC Filing	06-07	MT
B. Riley Cuts Price Target on Cytokinetics to $92 From $122, Maintains Buy Rating	06-04	MT
Cytokinetics Insider Sold Shares Worth $635,978, According to a Recent SEC Filing	06-03	MT
Truist Securities Lowers Price Target on Cytokinetics to $70 From $86, Maintains Buy Rating	05-29	MT
JMP Securities Adjusts Cytokinetics Price Target to $78 From $106, Maintains Market Outperform Rating	05-28	MT
Raymond James Adjusts Price Target on Cytokinetics to $70 From $92, Maintains Outperform Rating	05-23	MT
Needham Adjusts Price Target on Cytokinetics to $72 From $108, Maintains Buy Rating	05-23	MT
Cytokinetics Plans $500 Million Common Stock Offering -- Shares Drop After Hours	05-22	MT
Oppenheimer Adjusts Cytokinetics Price Target to $106 From $107, Maintains Outperform Rating	05-09	MT
Cytokinetics Insider Sold Shares Worth $1,012,265, According to a Recent SEC Filing	05-07	MT
Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing	04-09	MT
Mizuho Securities Adjusts Price Target on Cytokinetics to $99 From $103, Maintains Buy Rating	03-06	MT
UBS Downgrades Cytokinetics to Neutral From Buy, Adjusts Price Target to $92 From $61	01-24	MT
Mizuho Securities Boosts Price Target on Cytokinetics to $103 From $80, Keeps Buy Rating	01-19	MT
B. Riley Raises Cytokinetics' PT to $122 From $66, Keeps Buy Rating; Notes Heightened Conviction in Aficamten Taking Dominant Market Share Cardiac Myosin Inhibitor Market	01-08	MT
Truist Securities Raises Cytokinetics' Price Target to $86 From $60, Buy Rating Kept	12-27	MT
Needham Raises Cytokinetics' Price Target to $108 From $60, Keeps Buy Rating	12-27	MT
HC Wainwright Raises Cytokinetics Price Target to $94 From $58, Maintains Buy Rating	12-27	MT
Cantor Fitzgerald Raises Cytokinetics Price Target to $101 From $65, Maintains Overweight Rating	12-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Cytokinetics, Incorporated Deutsche Boerse AG

Equities

KK3A

US23282W6057

Analyst Reco.

Filters